UM-UC-3-luc Orthotopic Mouse Model Service for Bladder Cancer

The UM-UC-3-luc orthotopic mouse model enables longitudinal, non-invasive tracking of human bladder tumor progression through bioluminescence imaging, offering a clinically translatable platform for assessing intravesical chemotherapy, targeted agents, and combination regimens in an orthotopic microenvironment. Alfa Cytology constructs and validates this luciferase-reporter model under rigorous quality standards, providing sponsors with quantitative tumor burden data, histopathological endpoints, and flexible dosing schedules tailored to early-stage preclinical development needs.

Overview of UM-UC-3-luc Orthotopic Mouse Model for Bladder Cancer

The UM-UC-3 cell line was originally isolated from a metastatic lymph node lesion of a male patient diagnosed with poorly differentiated, high-grade transitional cell carcinoma of the urinary bladder. Genetically, UM-UC-3 carries an activating KRAS mutation (G12C), a missense mutation in TP53 (c.338T>G), and exhibits partial loss of PTEN alongside homozygous deletion of CDKN2A (INK4A). Its molecular signature is basal-like and mesenchymal, characterized by high vimentin and N-cadherin expression, absence of E-cadherin and uroplakin, and elevated MMP-9, EGFR, and VEGF-A levels—features that closely mirror aggressive, muscle-invasive human bladder cancer. The hypotriploid karyotype (modal chromosome number 80) further underscores its genomic instability.

Fig 1. Establishment of an intra-vesicle (IB) instillation based human UCC mouse model. (Gills, Jessie, et al., 2018)

When transduced with a stable luciferase reporter and instilled intravesically into immunodeficient hosts, UM-UC-3-luc cells adhere to the lamina propria and progress from microscopic foci to superficial carcinoma and ultimately muscle-invasive disease within approximately three weeks. Tumor establishment is enhanced by bladder preconditioning with poly-L-lysine or trypsin, which disrupts the protective glycosaminoglycan layer and facilitates cancer cell attachment. The luciferase tag permits real-time quantification of tumor burden through the abdominal wall, with photon emission linearly correlated to viable cell number—a feature that dramatically reduces cohort sizes and enables kinetic response profiling. This model has been validated against clinically relevant intravesical agents such as mitomycin C and systemic chemotherapeutics including cisplatin and gemcitabine, demonstrating dose-dependent tumor growth inhibition that parallels human treatment outcomes.

Cell Line Information: UM-UC-3-luc

UM-UC-3-luc is a luciferase-expressing derivative of the UM-UC-3 human bladder carcinoma line, engineered via lentiviral transfection to enable bioluminescence-based tumor monitoring. The parental line was deposited by the University of Michigan as part of a panel of urothelial cancer lines and remains one of the most extensively characterized models of muscle-invasive bladder cancer.

Our Services

Alfa Cytology delivers the UM-UC-3-luc orthotopic bladder cancer model as a fully managed preclinical service, from lentiviral luciferase validation and cell banking to surgical instillation, longitudinal bioluminescence imaging, and terminal histopathology. Our team employs optimized bladder preconditioning protocols—including poly-L-lysine or trypsin pre-treatment, controlled dwell times, and urethral clamping techniques—to achieve engraftment rates exceeding 90% while minimizing reflux-related complications. Each study is supported by weekly imaging cohorts, body weight surveillance, and customizable endpoint panels, ensuring your compound’s efficacy signal is captured with statistical rigor and regulatory traceability.

Workflow of UM-UC-3-luc Orthotopic Mouse Model Construction

Establishment of the UM-UC-3-luc orthotopic bladder tumor model centers on transurethral intravesical instillation into immunodeficient hosts, leveraging bladder preconditioning and precise procedural controls to maximize engraftment fidelity and longitudinal data quality. The protocol has been refined to reduce kidney reflux, standardize initial tumor burden, and ensure linear bioluminescence quantification throughout the study duration.

1. Luciferase Cell Line Validation and Banking: UM-UC-3-luc cells are verified for stable luciferase expression via in vitro bioluminescence assays, confirming a linear relationship between photon output and cell number (R² > 0.95). Mycoplasma PCR, STR profiling, and viability testing (>90% by trypan blue exclusion) are performed on each master cell bank aliquot prior to release for implantation.
2. Host Preparation and Anesthesia: Female athymic nude mice, 6–8 weeks of age, are acclimatized for a minimum of one week. On the day of surgery, mice are anesthetized with isoflurane (3% induction, 1.8% maintenance at 2 L/min oxygen), placed on a heated pad, and monitored continuously for respiratory pattern and skin color. Ophthalmic ointment is applied to prevent corneal desiccation.
3. Bladder Evacuation and Preconditioning: The bladder is gently emptied by manual compression of the lower abdomen. A lubricated 24-gauge or 25-gauge catheter is advanced transurethrally to approximately 1 cm from the urethral meatus, avoiding contact with the bladder wall to prevent hemorrhage. Fifty microliters of 0.1% poly-L-lysine or 0.25% trypsin (prewarmed to 37 °C) is instilled and allowed to dwell for 15 minutes to disrupt the urothelial glycosaminoglycan barrier and enhance cancer cell adhesion.
4. Tumor Cell Instillation and Urethral Clamping: UM-UC-3-luc cells are resuspended in complete growth medium (not PBS) to maintain viability during the procedure. A suspension of 3×10⁶ cells in 50 µL is slowly instilled through the catheter. A Vascu-Statt plastic clamp or lightweight surgical clip (∼20 g) is applied around the urethral meatus to prevent leakage, and the cell suspension is retained in the bladder for 1.5 hours under continuous anesthesia. This dwell time balances engraftment efficiency against reflux risk, reducing kidney tumor incidence to <4%.
5. Post-Procedure Recovery: Following the dwell period, the clamp and catheter are removed, and the bladder is allowed to empty spontaneously. Mice are transferred to a heated recovery chamber and monitored until fully ambulatory and urinating normally. Analgesia is administered according to institutional IACUC guidelines. Body weights are recorded daily for the first three post-operative days and twice weekly thereafter.
6. Longitudinal Bioluminescence Imaging and Endpoint Assessment: Tumor engraftment and growth are monitored via weekly bioluminescence imaging (IVIS or equivalent) following intraperitoneal luciferin injection, with photon flux quantified within standardized regions of interest. Corroborative high-frequency micro-ultrasound or micro-CT imaging is performed at selected timepoints to visualize tumor morphology and bladder wall invasion. At study endpoint, bladders are harvested, weighed, and processed for H&E staining, IHC profiling (Ki-67, cleaved caspase-3, CD31), and bioluminescence correlation validation.

Fig 2. UM-UC-3-luc Orthotopic Mouse Model construction workflow.

Case Study-UM-UC-3-luc Orthotopic Mouse Model Development

In a recent preclinical program, Alfa Cytology deployed the UM-UC-3-luc orthotopic model to assess the intravesical activity of an investigational agent against established bladder tumors. Following poly-L-lysine preconditioning and intravesical instillation, tumors were allowed to engraft and expand for one week, after which bioluminescence imaging confirmed uniform tumor take across the cohort. Animals were then randomized into treatment and vehicle control groups, with weekly bioluminescence readouts capturing tumor kinetics throughout the dosing window. At study termination, excised bladders underwent gravimetric analysis and comprehensive histopathological evaluation, revealing treatment-associated reductions in tumor cellularity, proliferation index, and microvessel density relative to controls. The integrated imaging and tissue dataset supported the sponsor’s preclinical decision-making and provided a foundation for subsequent pharmacology and toxicology planning.

Why Choose Alfa Cytology?

Selecting Alfa Cytology as your partner for UM-UC-3-luc orthotopic bladder cancer studies ensures access to a technically optimized, imaging-integrated model platform managed by scientists with deep expertise in urothelial cancer biology and intravesical delivery systems.

• High Engraftment Rates: Our refined preconditioning and clamping protocols consistently achieve >90% tumor take, minimizing animal usage and study variability.
• Real-Time Quantitative Tracking: Stable luciferase expression combined with calibrated IVIS imaging allows precise, non-invasive tumor burden quantification at multiple timepoints.
• Clinically Relevant Drug Routes: We support both intravesical instillation and systemic administration paradigms, enabling head-to-head comparison of local versus systemic therapeutic strategies.
• Multimodal Imaging Correlation: Bioluminescence data are validated against micro-ultrasound and micro-CT measurements, ensuring robust cross-platform tumor size confirmation.
• Comprehensive Endpoint Analysis: Terminal assessments include bladder weight, H&E histopathology, proliferation and apoptosis IHC, and angiogenic marker profiling.
• Adaptive Study Architecture: Protocols are tailored to your compound class—whether small-molecule cytotoxics, antibody-drug conjugates, or immuno-modulatory agents—with milestone-driven reporting.

Contact Us

Interested in leveraging the UM-UC-3-luc orthotopic model for your bladder cancer therapeutic program? Contact us now to discuss your target profile, preferred dosing route, and imaging schedule—our preclinical team will design a customized study plan, provide a detailed quotation, and guide your project from model validation through data delivery.

For research use only. Not intended for any clinical use.